WhiteSwell is a patient-focused company dedicated to improving treatment of acute decompensated heart failure (ADHF), a primary cause of repeat hospitalization and emergency room visits.

Concurrent with initial treatment, identification of the precipitant of HF decompensation is a primary goal of early management. In other words, why did the patient decompensate?

A recent study utilized a machine learning-based approach to identify, understand, and predict diuretic responsiveness in patients with acute decompensated heart failure (ADHF).

Among patients with acute decompensated heart failure, device-based thoracic duct decompression demonstrated the ability to reduce congestion safely, according to results of a first-in-human study.

Navigating TAVR Failure Using App-Guided Decision Making Case 2: Flail MV with Shock in a Non-operative Patient Within the prior 24 months, I have had a financial relationship with a company producing ...

A multicenter study has identified a potential new treatment for acute heart failure, a leading cause of hospitalization and death.

Reprieve Cardiovascular, Inc., a development-stage company focused on advancing acute decompensated heart failure (ADHF) treatment, today announced th ...

PATIENTS in congestive heart failure have a tendency to contract pulmonary infections. Conversely, pulmonary infections often precipitate bouts of cardiac decompensation in patients with heart dise ...

Catheter Precision to Acquire Assets in Development for Late-Stage Treatment for Acute Decompensated Heart Failure Provided by GlobeNewswire Apr 23, 2025 5:00am ...

Early initiation of the sodium glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin did not result in a statistically significant improvement in diuretic efficiency relative to structured ...

Infections in Patients with Decompensated Heart Failure are Common—and Dire —These findings suggest that 1 in 4 patients admitted with primary heart failure will also be diagnosed with an ...

MILFORD, Mass. & FRANKFURT, Germany, December 16, 2024--Reprieve Cardiovascular, Inc., a development-stage company focused on advancing acute decompensated heart failure (ADHF) treatment, today ...